Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Hepatitis

New Jersey Department of Health Joins in World Hepatitis Day July 28

Trenton, NJ, July 28, 2017 — In recognition of World Hepatitis Day, the New Jersey Department of Health is joining the World Health Alliance (WHA) and the World Health Organization (WHO) to raise awareness about the global burden of viral hepatitis.

Viral hepatitis is inflammation of the liver caused by a virus. The most common types are hepatitis A, B and C — three different contagious liver infections caused by unrelated viruses.

Hepatitis A typically occurs in an “acute” or time-limited form, while hepatitis B and C can develop into a life-long, chronic illness. Continue reading

Rutgers-Chaired Study Committee Announces Recommendations for Eliminating Viral Hepatitis

Dr. Brian Strom

New Brunswick, NJ, March 29, 2017 — Viral hepatitis could become rare — and approximately 20,000 deaths annually in the U.S. could be eliminated — if federal and state agencies make the disease a priority, according to recommendations of the National Academies of Sciences, Engineering, and Medicine announced today in Washington, D.C.

“Many people suffering from viral hepatitis are not in contact with the health system, so the elimination strategy must give as much attention to the delivery of services as to the services themselves,” said Brian L. Strom, M.D., M.P.H., a renowned epidemiologist and the chancellor of Rutgers Biomedical and Health Sciences, who headed the committee of scientists selected by the Academies which studied the issue and developed the recommendations. Continue reading

PhRMA Report: Eliminating Hepatitis C Could Reduce Future U.S. Health Care Spending by $115 Billion Over Decade

Washington, DC, October 24, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that a new study by Milliman on the clinical burden of hepatitis C projects that the incremental cost of hepatitis C to the U.S. health care system is projected to be $115 billion over the next decade.

The report estimates that, in the absence of a cure for hepatitis C, more than 350,000 patients would be living with advanced stages of the disease — including 100,000 more with cirrhosis of the liver and 250,000 more patients with end stage liver disease — by 2025. Continue reading

Report: Eliminating Hepatitis C Could Reduce Future U.S. Health Care Spending by $115 Billion Over Next Decade

Washington, DC, September 27, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that a new study by Milliman on the clinical burden of hepatitis C projects that the incremental cost of hepatitis C to the U.S. health care system is projected to be $115 billion over the next decade.

The report estimates that, in the absence of a cure for hepatitis C, more than 350,000 patients would be living with advanced stages of the disease — including 100,000 more with cirrhosis of the liver and 250,000 more patients with end stage liver disease — by 2025.

According to the report, government programs would bear a significant share of this burden. The Medicare program would spend an additional $30.4 billion, while Medicaid would incur additional spending of $21.5 billion. Continue reading